ABSTRACT
Objective: Using Meta-analysis to evaluate the vaccine effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) against invasive Streptococcus pneumoniae disease (IPD) caused by serotype 19A in children <5 years old. Methods: "Streptococcus pneumoniae infection""invasive pneumococcal disease""13-valent pneumococcal polysaccharide conjugate vaccine""PCV13""effectiveness""infant""child" and related terms were searched from China National Knowledge Infrastructure (CNKI), WANFANG DATA, PubMed, SCOPUS and Web of science with no limited on language, region and research institution. The retrieval time was limited from January 2010 to February 2023 and cohort study, case-control study and randomized controlled trial were included. Data were extracted from eligible studies by two independent reviewers, and after study quality assessment by NOS scale, Meta-analysis was completed using Stata 16.0 software. Results: A total of 2 340 related literatures were searched, and 10 literatures were finally included, including 5 case-control studies and 5 indirect cohort studies, which showed good literature quality. The vaccine effectiveness against serotype 19A IPD of PCV13 in children was 83.91% (95%CI: 78.92%-88.89%), and the subgroup analysis (P=0.240) showed there was no significant difference among the case-control study (VE=87.34%, 95%CI:79.74%-94.94%) and the indirect cohort study (VE=81.30%, 95%CI:74.69%-87.92%). The funnel plot and Egger test suggested that the possibility of publication bias was small. Conclusion: The present evidence indicates that PCV13 has a good vaccine effectiveness against serotype 19A IPD in children, and it is recommended to further increase the vaccination rate of PCV13 to reduce the disease burden of IPD in children <5 years old.
Subject(s)
Child , Humans , Child, Preschool , Case-Control Studies , Cohort Studies , Serogroup , Vaccines, Conjugate/therapeutic use , China , Pneumococcal Infections/prevention & controlABSTRACT
Objective: Using Meta-analysis to evaluate the vaccine effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) against invasive Streptococcus pneumoniae disease (IPD) caused by serotype 19A in children <5 years old. Methods: "Streptococcus pneumoniae infection""invasive pneumococcal disease""13-valent pneumococcal polysaccharide conjugate vaccine""PCV13""effectiveness""infant""child" and related terms were searched from China National Knowledge Infrastructure (CNKI), WANFANG DATA, PubMed, SCOPUS and Web of science with no limited on language, region and research institution. The retrieval time was limited from January 2010 to February 2023 and cohort study, case-control study and randomized controlled trial were included. Data were extracted from eligible studies by two independent reviewers, and after study quality assessment by NOS scale, Meta-analysis was completed using Stata 16.0 software. Results: A total of 2 340 related literatures were searched, and 10 literatures were finally included, including 5 case-control studies and 5 indirect cohort studies, which showed good literature quality. The vaccine effectiveness against serotype 19A IPD of PCV13 in children was 83.91% (95%CI: 78.92%-88.89%), and the subgroup analysis (P=0.240) showed there was no significant difference among the case-control study (VE=87.34%, 95%CI:79.74%-94.94%) and the indirect cohort study (VE=81.30%, 95%CI:74.69%-87.92%). The funnel plot and Egger test suggested that the possibility of publication bias was small. Conclusion: The present evidence indicates that PCV13 has a good vaccine effectiveness against serotype 19A IPD in children, and it is recommended to further increase the vaccination rate of PCV13 to reduce the disease burden of IPD in children <5 years old.
Subject(s)
Child , Humans , Child, Preschool , Case-Control Studies , Cohort Studies , Serogroup , Vaccines, Conjugate/therapeutic use , China , Pneumococcal Infections/prevention & controlABSTRACT
Objective To determine factors influencing the immunization of measles vaccine(MV) among health care workers in Hangzhou, and to provide recommendations to promote their MV immunization. Methods In 2016, we used typical sampling method to select 2 general hospitals of 3 different levels, 1 infectious diseases hospital and 1 children's hospital, and interviewed health care workers in high and low measles risk departments to investigate their MV immunization by using a structured questionnaire. Factors influencing their immunization were analyzed by logistic regression model. Results A total of 141 of 349 health care workers investigated had MV immunization history, and the MV immunization coverage rate was 40.40%.The logistic regression analysis showed that working in low measles risk department(OR=1.91, 95%CI: 1.20-3.04) was risk factors for MV immunization, and having confidence with the effectiveness of MV(OR=0.40, 95%CI: 0.21-0.78) . Knowing the "measles vaccination suggestion" (OR=0.50, 95%CI: 0.28-0.91) and the hospital had organized measles vaccination for health care workers in recent years(OR=0.35, 95%CI: 0.22-0.57) were protective factors for MV immunization. Conclusions Health care workers in Hangzhou had low MV coverage but high willingness. We should enhance education activity of MV immunization and organize measles vaccination for health care worker at regular intervals by hospitals to increase the MV coverage.
ABSTRACT
Astrocyte elevated gene 1 (AEG-l), an important oncogene, has been confirmed to play a crucial role in progression (invasion, metastasis, angiogenesis and chemoresistance, etc) of multiple cancers. Over the past decade, studies have shown that AEG-l is overexpressed in cancers involving almost all organs, including neuroblastoma, melanoma, HCC, breast, prostate cancer, etc. Moreover, AEG-l is associated with multiple pathways including PI3/Akt and nuclear factor-kappa;B; (NF-kappa;B;). This review mainly outlines the multiple regulating role of AEG-l in the development and progression of tumor and to discuss its role as a novel target for treatment of malignant tumors.